Search by BoMiProt ID - Bomi10262

Primary Information

BoMiProt ID Bomi10262
Protein Name Ubiquitin-conjugating enzyme E2 N/E2 ubiquitin-conjugating enzyme N/Ubiquitin carrier protein N/Ubiquitin-protein ligase N
Organism Bos taurus
Uniprot IDQ0P5K3
Milk FractionWhey
Ref Sequence ID NP_001069726.1
Aminoacid Length 152
Molecular Weight 17138
FASTA Sequence Download
Gene Name UBE2N
Gene ID 541130
Protein Existence Status reviewed

Secondary Information

Protein Function The ubiquitin conjugating enzyme E2 N (UBE2N) is involved in the tumorigenesis of several tumors.
Biochemical Properties The ubiquitin conjugating enzyme E2 N (UBE2N), also known as Ubc13, is a member of the E2 ubiquitin-conjugating enzyme family.It has been proved that UBE2N heterodimerized with UBE2V1 and UBE2V2, and the heterodimers catalyzed the synthesis of noncanonical lysine-63-linked polyubiquitin chains, which did not lead to proteasome-dependent protein degradation, but mediated target genes' transcriptional activation.
PTMs N-6 Acetylation at Lys, Isopeptide bond formation,Ubl conjugation
Site(s) of PTM(s)

N-glycosylation, O-glycosylation,
Predicted Disorder Regions NA
DisProt Annotation
TM Helix Prediction No TM helices
Significance of PTMs Ubl Conjugation to ISG15 impairs formation of the thioester bond with ubiquitin.
Additional Comments knockdown of UBE2N decreased the activation of MEK1/2 and p38 in cervical carcinoma cells, and UBE2N knockdown also markedly inhibited cervical carcinoma cell growth. 
Bibliography 1.Song TT, Xu F, Wang W. Inhibiting ubiquitin conjugating enzyme E2 N by microRNA-590-3p reduced cell growth of cervical carcinoma. Kaohsiung J Med Sci. 2020 Jul;36(7):501-507. doi: 10.1002/kjm2.12204. Epub 2020 Mar 20. PMID: 32196955. 2.Bailey J, Davis S, Shaw A, Diotallevi M, Fischer R, Benson MA, et al. Tetrahydrobiopterin modulates ubiquitin conjugation to UBC13/UBE2N and proteasome activity by S-nitrosation. Sci Rep. 2018;8:14310. 3.Hodge CD, Spyracopoulos L, Glover JN. Ubc13: the Lys63 ubiquitin chain building machine. Oncotarget. 2016;7:64471–64504.